SciSparc (SPRC) Competitors $7.54 -0.50 (-6.22%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.68 +0.14 (+1.86%) As of 07/18/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. FLGC, ALLR, MTEX, EDSA, PMN, SNPX, HOOK, LEXX, NEUP, and ERNAShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Flora Growth (FLGC), Allarity Therapeutics (ALLR), Mannatech (MTEX), Edesa Biotech (EDSA), Promis Neurosciences (PMN), Synaptogenix (SNPX), HOOKIPA Pharma (HOOK), Lexaria Bioscience (LEXX), Neuphoria Therapeutics (NEUP), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Flora Growth Allarity Therapeutics Mannatech Edesa Biotech Promis Neurosciences Synaptogenix HOOKIPA Pharma Lexaria Bioscience Neuphoria Therapeutics Ernexa Therapeutics SciSparc (NASDAQ:SPRC) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Do institutionals & insiders believe in SPRC or FLGC? 25.1% of SciSparc shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 12.6% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is SPRC or FLGC more profitable? SciSparc has a net margin of 0.00% compared to Flora Growth's net margin of -24.85%. SciSparc's return on equity of 0.00% beat Flora Growth's return on equity.Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Flora Growth -24.85%-216.49%-45.56% Which has more risk and volatility, SPRC or FLGC? SciSparc has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Does the media prefer SPRC or FLGC? In the previous week, SciSparc had 1 more articles in the media than Flora Growth. MarketBeat recorded 1 mentions for SciSparc and 0 mentions for Flora Growth. SciSparc's average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score. Company Overall Sentiment SciSparc Neutral Flora Growth Neutral Which has better earnings and valuation, SPRC or FLGC? SciSparc has higher earnings, but lower revenue than Flora Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.31M3.05-$6.28MN/AN/AFlora Growth$59.51M0.24-$15.91M-$0.98-0.63 Do analysts rate SPRC or FLGC? Flora Growth has a consensus target price of $4.00, indicating a potential upside of 545.16%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Flora Growth 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryFlora Growth beats SciSparc on 7 of the 13 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.30M$2.46B$5.55B$9.40BDividend YieldN/A1.80%3.75%4.03%P/E RatioN/A8.9428.0119.82Price / Sales3.05709.92432.8198.20Price / CashN/A164.7736.1658.27Price / Book0.425.008.125.65Net Income-$6.28M$30.99M$3.25B$257.91M7 Day Performance7.87%1.69%1.68%3.38%1 Month Performance20.28%9.20%7.30%11.11%1 Year Performance-44.16%0.43%32.89%18.99% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.7788 of 5 stars$7.54-6.2%N/A-50.8%$4.30M$1.31M0.004FLGCFlora Growth2.4989 of 5 stars$0.68-1.5%$4.00+489.1%-42.9%$15.57M$53.26M-0.70280ALLRAllarity Therapeutics0.6611 of 5 stars$1.03-1.9%N/A-82.2%$15.53MN/A0.0010Positive NewsMTEXMannatech1.2176 of 5 stars$8.14-4.2%N/A+11.9%$15.47M$117.87M-81.40250Positive NewsEDSAEdesa Biotech1.4693 of 5 stars$2.16-1.8%$5.00+131.4%-48.7%$15.17MN/A-1.3620Positive NewsPMNPromis Neurosciences3.1529 of 5 stars$0.44-15.0%$4.33+880.4%-78.9%$14.48MN/A-8.865News CoverageAnalyst RevisionGap UpHigh Trading VolumeSNPXSynaptogenix0.2484 of 5 stars$10.38+15.5%N/A+118.6%$14.43MN/A-1.034Positive NewsGap UpHigh Trading VolumeHOOKHOOKIPA Pharma3.2305 of 5 stars$1.18-2.1%$4.50+283.0%-82.0%$14.32M$43.95M-0.20160News CoveragePositive NewsTrading HaltedLEXXLexaria Bioscience1.7712 of 5 stars$0.81-2.4%$5.00+514.3%-65.7%$14.29M$460K-1.387Earnings ReportNEUPNeuphoria Therapeutics1.887 of 5 stars$7.60-1.3%$21.00+176.3%N/A$14.29M$15.66M0.00N/ANews CoverageERNAErnexa Therapeutics0.2553 of 5 stars$1.92-2.3%N/A-93.8%$14.10M$535K-0.2310Gap Up Related Companies and Tools Related Companies FLGC Alternatives ALLR Alternatives MTEX Alternatives EDSA Alternatives PMN Alternatives SNPX Alternatives HOOK Alternatives LEXX Alternatives NEUP Alternatives ERNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
